Novartis Reports the Reimbursement of Kisqali as 1L Treatment for Metastatic Breast Cancer in Quebec

Novartis Reports the Reimbursement of Kisqali as 1L Treatment for Metastatic Breast Cancer in Quebec

Shots:

  • The reimbursement of Kisqali is a testament to the ongoing need for public access to the treatment. The Canadian Province, Quebec will reimburse Kisqali + Letrozole under the public drug program as 1L treatment for HR+, HER2-negative advanced or metastatic breast cancer in post-menopausal women
  • Novartis will collaborate with remaining province and territories in Canada ensuring the access of Kisqali to the patients & healthcare providers
  • Kisqali is a selective cyclin-dependent kinase inhibitor, act by inhibiting CDK4/6 thus ensure that cancer cells do not continue to replicate uncontrollably and was developed by Novartis Institutes for BioMedical Research in collaboration with Astex Pharmaceuticals

Click here to­ read full press release/ article | Ref: PRNewswire | Image: Pharmaceutical Technology